Anupam Rasayan India Ltd. Rating Maintained Under Negative Watch

Anupam Rasayan India Ltd.'s issuer rating has been maintained at IND AA- with a Negative Watch by the rating agency. The rating agency also maintained the rating for existing bank loan facilities and assigned ratings for new bank loan facilities and non-convertible debentures at IND AA- / A1+ with a Negative Watch.

Consolidated Revenue FY26: INR 23,655 million (up 65% YoY)
Consolidated EBITDA FY26: INR 5,248 million (up 32% YoY)

Reader Takeaway: Strong revenue growth is positive, but margin contraction and acquisition funding pose challenges.

What just happened

Anupam Rasayan India Ltd. saw its Issuer Rating maintained at 'IND AA- (Negative Watch)'. The rating agency also maintained existing bank loan facilities and assigned new ones, along with non-convertible debentures, all carrying the same 'IND AA- / A1+ (Negative Watch)' rating. This reflects ongoing scrutiny of the company's financial health, particularly concerning its proposed acquisition.

Why this matters

The 'Negative Watch' indicates that the rating agency is closely monitoring specific factors that could potentially lead to a downgrade. For investors, this means increased uncertainty about the company's creditworthiness, which can impact borrowing costs and overall financial stability. The acquisition of Bliss GVS Pharma is a key event influencing this watch.

The backstory

Anupam Rasayan is a leading custom synthesis and specialty chemical company. The company has been expanding its capacity and product portfolio. Its recent financial performance showed robust revenue growth, but a decline in EBITDA margins from 27.6% in FY25 to 22.2% in FY26 due to a one-time event is a point of concern.

What changes now

The company is acquiring a 43.3% stake in Bliss GVS Pharma for INR 13,695 million, with an open offer for an additional 26%. The funding involves INR 3,000 million in term loans and non-controlling equity instruments. The rating agency is specifically monitoring the final capital structure and leverage post-acquisition.

Risks to watch

The primary risk is the uncertainty surrounding the final capital structure post-acquisition. The consolidated adjusted net leverage currently stands at 3.1x. High customer concentration, with the top five customers accounting for 49% of standalone FY26 revenue, also presents a business continuity risk.

Peer comparison

(No specific peer comparison data provided in the filing).

Context metrics (time-bound)

• Consolidated revenue grew 65% YoY to INR 23,655 million in FY26.
• Consolidated EBITDA grew 32% YoY to INR 5,248 million in FY26.
• EBITDA margin contracted to 22.2% in FY26 from 27.6% in FY25.
• Adjusted net leverage is 3.1x in FY26, down from 3.5x in FY25.
• Acquisition of Bliss GVS Pharma for INR 13,695 million.

What to track next

Investors should closely monitor the completion of the Bliss GVS Pharma acquisition, the finalization of its funding structure, and any subsequent communication from the rating agency regarding the 'Negative Watch'. Management's efforts to improve EBITDA margins in FY27 will also be crucial.